Medicinova (MNOV) EBITDA (2010 - 2025)

Medicinova (MNOV) has 16 years of EBITDA data on file, last reported at -$3.1 million in Q4 2025.

• On a quarterly basis, EBITDA rose 2.87% year-over-year to -$3.1 million in Q4 2025; TTM through Dec 2025 was -$13.3 million, a 4.79% decrease from a year earlier, with the FY2025 full-year figure at -$13.3 million, down 4.79% from the prior year.
• EBITDA for Q4 2025 stood at -$3.1 million, up from -$3.4 million in the prior quarter.
• Over the last five years, EBITDA for MNOV reached as high as -$201529.0 in Q1 2021 and fell as low as -$4.3 million in Q2 2021.
• Historically, EBITDA has averaged -$3.0 million across 5 years, with a median of -$3.2 million in 2022.
• Across the five-year window, EBITDA surged 93.11% in 2021 and plunged 1592.07% in 2022, its largest moves.
• Year by year, EBITDA stood at -$2.1 million in 2021, then slumped by 53.66% to -$3.2 million in 2022, then climbed by 22.94% to -$2.5 million in 2023, then retreated by 27.85% to -$3.2 million in 2024, then increased by 2.87% to -$3.1 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$3.1 million in Q4 2025, -$3.4 million in Q3 2025, and -$3.6 million in Q2 2025.